血管運動神経症状の市場規模、シェア、成長分析、治療の種類別、流通チャネル別、エンドユーザー別、地域別 - 産業予測 2025-2032年

血管運動神経症状市場規模は2023年に37億4,000万米ドルとなり、予測期間（2025-2032年）のCAGRは6.9%で、2024年の40億米ドルから2032年には68億2,000万米ドルに成長する見通しです。

市場の洞察によると、血管運動神経症状は月経中の女性が報告する最も一般的な問題であり、主にほてり、寝汗、貧血を特徴とします。これらの症状は、特に首、顔、額に突然の熱感や過剰な発汗をもたらします。動悸の頻度や強さも、特に閉経後2年間は大きく変動し、この時期が特に課題となります。多くの女性にとって、このような衰弱症状は永続的なものとなる可能性があり、月経経験の個人的な側面が強調されています。さらに、多面的な神経症状が複雑であることから、社会的力学が進化する中でこの過渡期を乗り切る女性が直面する特有の課題に対処するために、それぞれに合った解決策が必要であることが強調されています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

血管運動神経症状市場規模：治療の種類別& CAGR（2025-2032）

• 市場概要
• エストロゲン
• プロゲステロン
• 組み合わせ
• 市販のホルモン剤
• 抗うつ薬
• その他

血管運動神経症状市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• ドラッグストア

血管運動神経症状市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院と診療所
• 専門センター
• その他

血管運動神経症状市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• TherapeuticsMD（United States）
• Mithra Pharmaceuticals（Belgium）
• KaNDy Therapeutics（United Kingdom）
• Fervent Pharmaceuticals（United States）
• Astellas Pharma（Japan）
• Sojournix（United States）
• Mitsubishi Tanabe Pharma（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Pfizer Inc.（United States）
• Hikma Pharmaceuticals PLC（United Kingdom）
• Dr. Reddy's Laboratories Ltd.（India）
• AbbVie Inc.（United States）
• Endo Pharmaceuticals PLC（Ireland）
• Novartis AG（Switzerland）
• Wockhardt（India）
• Bayer AG（Germany）
• Eli Lilly and Company（United States）
• Sun Pharmaceutical Industries Ltd.（India）
• Alembic Pharmaceuticals Limited（India）
• Zydus Group（India）

結論と提言

Vasomotor Symptoms Market size was valued at USD 3.74 billion in 2023 and is poised to grow from USD 4.0 billion in 2024 to USD 6.82 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

Market insights reveal that vasomotor symptoms are the most prevalent issues reported by women during menstruation, primarily characterized by hot flashes, night sweats, and anemia. These symptoms can lead to sudden sensations of heat and excessive sweating, particularly on the neck, face, and forehead. The frequency and intensity of heart palpitations also exhibit significant variability, especially during the first two years of menopause, marking this period as particularly challenging. For many women, these debilitating symptoms may become permanent, underlining the individual aspects of menstrual experiences. Furthermore, the complexity of multidimensional neurological symptoms emphasizes the necessity for tailored solutions to address the unique challenges faced by women navigating this transitional phase amidst evolving social dynamics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Vasomotor Symptoms market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Vasomotor Symptoms Market Segments Analysis

Global Vasomotor Symptoms Market is segmented by Therapy Type, Distribution Channel, End User and region. Based on Therapy Type, the market is segmented into Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Drug Stores. Based on End User, the market is segmented into Hospitals and Clinics, Specialty Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Vasomotor Symptoms Market

Research and development (R&D) efforts and clinical trials are crucial in enhancing our comprehension of the mechanisms behind neurological symptoms, such as physiological changes and genetic mutations. This deeper insight can lead to the creation of more precise and effective therapies. As researchers delve into the complexities of neurological disorders through clinical trials, they contribute significantly to the market's strong compound annual growth rate (CAGR). These trials not only broaden the spectrum of available treatments but also stimulate market expansion by introducing groundbreaking therapeutic solutions, thereby driving advancements in the Vasomotor Symptoms market.

Restraints in the Vasomotor Symptoms Market

The Vasomotor Symptoms market faces significant constraints due to the high expenses linked with many treatment options. Market participants frequently allocate considerable resources towards developing innovative treatment strategies aimed at enhancing recovery outcomes, which consequently drives up overall costs. These hefty investments in research, development, and production lead to increased prices associated with different treatment modalities. Although these advancements offer the potential for improved patient outcomes and effectiveness of therapies, the associated higher costs create obstacles to the overall growth of the market, limiting accessibility and affordability for patients seeking relief from vasomotor symptoms.

Market Trends of the Vasomotor Symptoms Market

The vasomotor symptoms (VMS) market is experiencing notable growth, fueled by the introduction of innovative interventions and treatments that enhance awareness of these symptoms-primarily among women experiencing menopause. As awareness rises, more women are actively seeking effective relief, expanding the market significantly. Companies that specialize in pioneering new therapies or products have a distinct opportunity to gain a competitive edge, particularly if they succeed in establishing their offerings as the preferred choice among healthcare providers and patients alike. This trend suggests a vibrant, evolving marketplace characterized by heightened demand for effective VMS management solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Vasomotor Symptoms Market Size by Therapy Type & CAGR (2025-2032)

• Market Overview
• Estrogen
• Progesterone
• Combination
• OTC hormone
• Anti-Depressants
• Others

Global Vasomotor Symptoms Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Drug Stores

Global Vasomotor Symptoms Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Specialty Centers
• Others

Global Vasomotor Symptoms Market Size & CAGR (2025-2032)

• North America (Therapy Type, Distribution Channel, End User)
  • US
  • Canada
• Europe (Therapy Type, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Distribution Channel, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• TherapeuticsMD (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mithra Pharmaceuticals (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KaNDy Therapeutics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fervent Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sojournix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo Pharmaceuticals PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alembic Pharmaceuticals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Group (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations